[Disclosure] Hanamicron(067310) Lists 5,500 New Shares Following Stock Option Exercise

Fact Source: Financial Supervisory Service – Data Analysis, Retrieval and Transfer System (DART) / 2024-03-21

Disclosure Type: Additional Listing (Exercise of Stock Options)

💡 3-Second Summary Hanamicron is listing 5,500 new shares following the exercise of stock options by employees.

📊 1. [Key Details and Figures]

• Additional Shares: 5,500 common shares
• Exercise Price: 9,275 KRW per share
• Par Value: 500 KRW
• Total Outstanding Shares Post-Listing: 48,074,154 shares

📈 2. [Expert Insight: Impact Analysis on Stock Price]

This additional listing is a routine event with negligible impact on market liquidity.

• Dilution Effect: Adding 5,500 shares to the total outstanding shares is statistically insignificant and has no practical dilution effect on existing shareholders.
• Strategic Interpretation: The exercise price of 9,275 KRW reflects internal compensation dynamics and serves as a subtle indicator of confidence from employees in the company’s growth outlook.
• Conclusion: This event should be interpreted as a confirmation of internal alignment and management sentiment rather than a factor affecting stock market volatility.

📝 Editor’s Comment (by K-STOCK Editor)

The volume of 5,500 shares is effectively noise. What matters is the exercise price of 9,275 KRW. The fact that employees are exercising these options suggests they see long-term upside potential at current levels. Don’t get caught up in the optics of ‘additional supply’; look at the signal of internal commitment. When you separate the data from the noise, this is simply a look at how the company incentivizes its talent—a story of internal confidence that is far more telling than the small number of shares being listed.

📢 Disclaimer Source: This content is structured and written based on official data submitted to the Financial Supervisory Service’s DART system. Investment Risk Notice: This content is provided for informational and reference purposes only. It does not constitute financial advice or a recommendation to buy or sell any stock. All investment decisions and financial responsibilities rest solely with the investor. Inquiry: For compliance or copyright-related matters, please contact ksb220805@gmail.com